ArticleBMC nephrology2025
Prevalence and prognostic impact of abnormal left ventricular ejection fraction in Hemodialysis patients with end-stage renal disease.
Article in BMC nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Article
- The Burden of Heart Failure in End-Stage Renal Disease: Insights from a Retrospective Cohort of Hemodialysis Patients.Journal of clinical medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundPatients with end-stage renal disease (ESRD) face a significantly elevated risk of cardiovascular morbidity and mortality, with left ventricular (LV) systolic dysfunction and heart failure (HF) being major contributors. Reduced left ventricular ejection fraction (LVEF) defines LV systolic dysfunction and is closely linked to adverse outcomes. This study aimed to assess the prevalence of abnormal LVEF in ESRD patients receiving hemodialysis and to examine the prognostic significance of varying LVEF levels on mortality and cardiovascular outcomes. METHODS AND
resultsA retrospective cohort study was conducted on 1,019 ESRD patients receiving hemodialysis at People's Hospital of Guangxi Zhuang Autonomous Region between January 1, 2020, and December 31, 2021. Based on baseline LVEF, patients were classified into three groups: reduced ejection fraction (LVEF ≤ 40%, rEF), mildly reduced ejection fraction (LVEF 41-49%, mrEF), and normal ejection fraction (LVEF ≥ 50%, nEF). Clinical outcomes, including all-cause mortality and major adverse cardiovascular events (MACEs), were analyzed to assess the impact of LVEF levels. During a median follow-up of 35 months (IQR, 31-51 months), 214 patients (21.0%) died, and 218 (21.4%) experienced MACEs. The prevalence of abnormal LVEF was 13.35%, with 7.55% of patients in the mrEF group and 5.80% in the rEF group. Patients with abnormal LVEF showed significantly higher rates of all-cause mortality and MACEs than those with normal LVEF. In the rEF group, the odds ratios (ORs) for all-cause mortality and MACEs were 2.91 (95% CI: 1.83-4.63, P < 0.001) and 4.76 (95% CI: 2.43-9.46, P < 0.001), respectively. In the mrEF group, ORs for all-cause mortality and MACEs were 1.69 (95% CI: 1.09-2.62, P = 0.019) and 2.68 (95% CI: 1.54-4.68, P < 0.001), respectively.
conclusionAbnormal LVEF is prevalent in ESRD patients on hemodialysis and is strongly associated with increased risks of all-cause mortality and MACEs. Lower LVEF levels correlate with poorer outcomes, underscoring the importance of early detection and targeted management strategies to improve prognosis in this high-risk population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.